Tradipitant Halves GLP-1 Agonist-Induced Vomiting—Key Milestone for Vanda in $50B Market
Study Results: Tradipitant Shows 50% Reduction in Vomiting Incidents
Vanda Pharmaceuticals (NASDAQ: VNDA) has reported that its lead pipeline asset, tradipitant, achieved significant results in preventing nausea and vomiting caused by GLP-1 receptor agonists—a class of drugs generating over $50 billion globally. In a randomized controlled study of 116 overweight and obese adults, only 29.3% of those pre-treated with tradipitant experienced vomiting, compared to 58.6% on placebo. This equates to a 50% relative reduction, a difference that reached high statistical significance (p = 0.0016).
| Endpoint | Placebo (N=58) |
Tradipitant (N=58) |
P-value |
|---|---|---|---|
| Proportion with vomiting | 58.6% (34/58) | 29.3% (17/58) | 0.0016 |
| Proportion with vomiting & worst nausea = 3* | 48.3% (28/58) | 22.4% (13/58) | 0.0039 |
* Moderate or worse nausea on a 0–5 severity scale
Positive Safety Profile and Improved Adherence Implications
Tradipitant's safety data mirrored prior studies, with no new safety concerns observed. The company emphasizes that GLP-1-induced gastrointestinal side effects lead to early treatment discontinuations for as many as 30–50% of patients—often before reaching doses needed for maximum benefit. By reducing nausea and vomiting, tradipitant could make a real difference for patients struggling to tolerate these therapies and for healthcare payors burdened by costs from unused medications and unaddressed obesity-related health risks.
Strong Market Context: GLP-1 Discontinuation a $50B Challenge
With the global GLP-1 agonist market surpassing $50 billion in just the first nine months of 2025, improving adherence remains an urgent priority. Vanda’s results also echo tradipitant’s established efficacy in reducing vomiting in motion sickness studies. As a result, the company now sees tradipitant as a potential “transformative adjunct” to widely prescribed GLP-1s like Wegovy®—drugs with major relevance in weight loss and diabetes care.
Development Pathway: Phase III and Regulatory Milestones on the Horizon
Vanda intends to pursue regulatory approval with a Phase III program expected in the first half of 2026. The FDA is already reviewing tradipitant for motion sickness, with an approval decision anticipated by the end of 2025. Should results remain consistent, tradipitant may soon become an essential option to keep patients on track with their GLP-1 therapy regimens.
What This Means for Investors and Patients
For patients, tradipitant offers hope for improved tolerability of high-impact weight loss medications. For investors and the pharmaceutical sector, the data present a pathway for Vanda to tap into a large, rapidly growing market. While forward-looking statements caution against overconfidence, this latest clinical win clearly moves tradipitant closer to approval for one of the largest opportunities in metabolic health today.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI